Alcon Q2 Sales Jump 8% to $2.8B, Raises Full-Year Margin and EPS Outlook
ALC sits 21% above its 52-week low of $61.835.
Summary
Alcon delivered a strong Q2 with sales of $2.8 billion, up 8% reported and 7% constant currency, driven by new product launches and commercial execution. Core diluted EPS rose to $0.84 from $0.76 a year ago. Management raised full-year guidance for core operating margin and core diluted EPS growth, signaling confidence in the innovation pipeline. Surgical equipment sales surged 25% cc, while Vision Care contact lenses gained market share. This follows a $1.5 billion buyback authorization announced in May and a $750 million program completed earlier in the year, underscoring robust capital returns. The raised outlook and broad-based growth across segments make this a material positive update for the stock.
At the time of this announcement, ALC was trading at $75.03 on NYSE in the Life Sciences sector, with a market capitalization of approximately $36.8B. The 52-week trading range was $61.84 to $90.41. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.